

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
DI-5924

In Re Application Of: Zieske et al.

DEC 02 2004

Examiner

E. Peselev

Application No.	Filing Date	Customer No.	Group Art Unit	Confirmation No.
10/628,065	July 25, 2003	29176	1614	4163

Title: DIALYSIS SOLUTIONS WITH REDUCED LEVELS OF GLUCOSE DEGRADATION PRODUCTS

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);


OR

the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
 DI-5924

In Re Application: Zieske et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/628,065	July 25, 2003	E. Peselev	29176	1614	4163

Title: DIALYSIS SOLUTIONS WITH REDUCED LEVELS OF GLUCOSE DEGRADATION PRODUCTS

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of \_\_\_\_\_ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.

- Charge the amount of \_\_\_\_\_
- Credit any overpayment.
- Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

\_\_\_\_\_  
 (Date)

\_\_\_\_\_  
 Signature

\_\_\_\_\_  
 Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

11-30-2004

\_\_\_\_\_  
 (Date)  


\_\_\_\_\_  
 Signature of Person Mailing Correspondence

Heather Foster

\_\_\_\_\_  
 Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

\_\_\_\_\_  
 Signature

Dated: November 30, 2004

Robert M. Barrett

Reg. No. 30,142

BELL, BOYD & LLOYD LLC

P.O. Box 1135

Chicago, IL 60690-1135


Phone: 312-807-4204

CC:

STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

Docket No.  
DI-5924

In Re Application Of: Zieske et al.



Application No. 10/628,065	Filing Date July 25, 2003	Examiner E. Peselev	Customer No. 29176	Group Art Unit 1614	Confirmation No. 4163
-------------------------------	------------------------------	------------------------	-----------------------	------------------------	--------------------------

Invention: DIALYSIS SOLUTIONS WITH REDUCED LEVELS OF GLUCOSE DEGRADATION PRODUCTS

COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Signature

Dated: November 30, 2004

Robert M. Barrett  
Reg. No. 30,142  
BELL, BOYD & LLOYD LLC  
P.O. Box 1135  
Chicago, IL 60690-1135  
Phone: 312-807-4204

Certificate of Mailing by First Class Mail

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

11-30-04

(Date)

Signature of Person Mailing Correspondence

Heather Foster

Typed or Printed Name of Person Mailing Correspondence

CC:



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Zieske et al.

Appl. No.: 10/628,065

Conf. No.: 4163

Filed: July 25, 2003

Title: DIALYSIS SOLUTIONS WITH REDUCED LEVELS OF GLUCOSE  
DEGRADATION PRODUCTS

Art Unit: 1614

Examiner: E. Peselev

Docket No.: DI-5924

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, be made during the course of examination of the above-identified application for United States patent. Pursuant to the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patents and patent applications are not included as this application was filed after June 30, 2003. However, copies of all other cited references are included with this form.

#### U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
6,309,673	October 30, 2001	Duponchelle et al.
6,277,815	August 21, 2001	Knerr

#### FOREIGN PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
EP 1 008 341 A1	June 14, 2000	Europe
WO 00/23086	April 27, 2000	PCT
JP 2000-245826	September 12, 2000	Japan

#### OTHER DOCUMENTS


Zheng et al., Heat sterilization of peritoneal dialysis solutions influences ingestive behavior in non-uremic rats, Kidney International, Vol. 62 (2002), pp. 1447-1453.

All of the cited references listed above are listed in a PCT Search Report for a PCT application corresponding to the present application. A copy of the Search Report is included with this submission.

Applicants look forward to early and favorable consideration of this matter.


Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY 

Robert M. Barrett  
Reg. No. 30,142  
P.O. Box 1135  
Chicago, Illinois 60690-1135  
Phone: (312) 807-4204

Dated: November 30, 2004



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)	Atty Docket No.	Application No.
	DI-5924	10/628,065
	Applicant	Zieske et al.
Filing Date	Group	
July 25, 2003	1614	

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	OTHER DOCUMENTS ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )
	Zheng et al., Heat sterilization of peritoneal dialysis solutions influences ingestive behavior in non-uremic rats, Kidney International, Vol. 62 (2002), pp. 1447-1453.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	